期刊
SEPARATION AND PURIFICATION TECHNOLOGY
卷 263, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.seppur.2021.118358
关键词
Biopurification; Protein crystallisation; Monoclonal antibody; Phase behaviour; Scale-up
资金
- UK's EPSRC [EP/N015916/1]
The review discusses the advantages of mAb crystallisation as an alternative biopurification technology, highlighting its high product stability, purity, and scalability. Successful demonstrations of mAb crystallisation scale-ups are presented, with a focus on critical factors such as mixing and temperature control.
Therapeutics based on monoclonal antibody (mAb) represent the most advanced biopharmaceuticals, being able to treat a wide range of challenging diseases such as cancers and arthritis. As the scale of mAb production steadily increases with the demand for mAb-based therapeutics, the downstream biopurification continues to experience significant bottleneck due to the throughput limited nature of the current purification technology. Over the last decades, significant advances have been made in protein (and especially mAb) crystallisation as an alternative biopurification technology that offers high product stability and purity as well as scalability. This review starts with the discussion of general physicochemical properties of mAb before moving on to the in-depth discussion of the distinct phase behaviour of mAb in comparison with conventional globular proteins such as lysozyme. The final part of this review presents a summary of successful demonstrations of crystallisation scale-ups of mAb and discusses the critical factors (i.e. mixing and temperature control) to be considered.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据